Communications with society
On the Copenhagen Culture Night, a team of CCS scientists held a 'Minilaboratorier/udstilling' called 'Oplev / Experience DNA'
Diverse activities were provided for the visitors, including observing chromosomes under microscopes, watching videos of mitosis of cells cultured in the lab, making double stranded DNA models, and extracting DNA from tomatoes using household materials.
October 13, 2023 - 'Oplev / Experience DNA', exhibition by CCS
October 14, 2022 - 'Oplev / Experience DNA', exhibition by CCS
October 15, 2021 - 'Oplev / Experience DNA', exhibition by CCS
October 11, 2019 - 'Oplev / Experience DNA', exhibition by CCS
October 12, 2018 - 'Oplev / Experience DNA', exhibition by CCS
Some of the CCS groups have established close working relationships with clinicians and clinical pathologist in Denmark and abroad. These collaborations will directly facilitate the development of improved treatment for patients with health disorders.
Some of the CCS groups have established close working relationships with clinicians and clinical pathologist in Denmark and abroad. These collaborations will directly facilitate the development of improved treatment for patients with health disorders.
The Hoffmann group collaborates with fertility clinics in Denmark and abroad as part of ReproUnion and the MeioMap Project. In 2017, they completed the first phase of collecting the largest number of human oocytes (over 1,200) from women in Denmark. During this process, they made close contacts with clinicians and patients. Their research results and discussions at the fertility clinics have the potential to benefit women who cannot undergo hormone therapy during infertility treatment.
In collaboration with clinical pathologists in Chengde, China, the Liu group has carried out a pilot study to analyze the expression of a panel of proteins that are known to play different roles during genome maintenance in a representative range of cancer types (colon, lung, breast or stomach). Their results indicated that it might be possible to identify biomarkers to aid the diagnosis and treatment for patients with different type of cancers (https://www.ncbi.nlm.nih.gov/pubmed/28445142). This group currently is collaborating with Chengde Medical University and affiliated hospital to develop a biomarker for gastric cancer, which is the second leading cause of cancer death in men and women in China.
A prestigious grant from the European Union for Future and Emerging Technologies (FET) development was given to research teams from the Netherlands, the UK and Denmark (including a team at the DTU, and the Hickson and Liu groups in the CCS), as well as Lumicks, a leading supplier of Dynamic Single-Molecule analysis instruments worldwide. This ambitious program aims to study chromosome structure and function in unprecedented detail via the utilization of advanced microfluidics and single molecule ‘tweezers’, and to translate this technology to industry. In the summer of 2018, the CCS will host one of the first commercial optical tweezers and imaging systems as part of its collaboration with Lumicks. The CCS will offer feedback on the technology to enable further development by Lumicks, such that this instrument could be used routinely in biology-based research centers.
CCS members are regularly invited to give advice on the development of treatment for cancer patients by pharmaceutical companies. For example, Prof. Ian Hickson has consulted with companies from the UK and Japan.